Patents by Inventor Stephen Paul Collingwood
Stephen Paul Collingwood has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090264459Abstract: Compounds of formula (I) in free or a pharmaceutically acceptable salt form, wherein X1, L and Q have the meanings as indicated in the specification, are useful for treating obstructive or inflammatory airways diseases. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.Type: ApplicationFiled: June 28, 2007Publication date: October 22, 2009Inventors: Stephen Paul Collingwood, Robin Alec Fairhurst, Neil John Press
-
Publication number: 20090227590Abstract: Compounds of formula (I), in salt or zwitterionic form, wherein J, L, M, R1, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.Type: ApplicationFiled: December 22, 2005Publication date: September 10, 2009Inventors: Neil John Press, Stephen Paul Collingwood
-
Publication number: 20090048281Abstract: Compounds of Formula (I); in salt or zwitterionic form wherein R1, R2, R3 and R4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.Type: ApplicationFiled: October 31, 2005Publication date: February 19, 2009Inventors: Neil John Press, Stephen Paul Collingwood, Urs Baettig, Brian Cox, Sudhakar Devidasrao Garad, Hyungchul Kim, Dimitris Papoutsakis, Simon James Watson
-
Publication number: 20080317862Abstract: Medicaments comprising (A) an antimuscarinic agent and (B) a corticosteroid for the treatment of inflammatory or obstructive airways diseases.Type: ApplicationFiled: November 20, 2006Publication date: December 25, 2008Inventors: Stephen Paul Collingwood, Barbara Haeberlin
-
Publication number: 20080312217Abstract: A Compound of formula (I) or tautomers, or stereoisomers, or solvates, or pharmaceutically acceptable salts thereof, wherein M1, M1, L1, L2, W1, W2, X1, X2, Y1, Y2, A, R5, and R5a are as defined herein for the treatment of conditions mediated by the blockade of an epithelial sodium channel, particularly an inflammatory or allergic condition.Type: ApplicationFiled: December 20, 2006Publication date: December 18, 2008Inventors: Stephen Paul Collingwood, Nichola Smith
-
Publication number: 20080312212Abstract: A compound of formula (I) or tautomers, or stereoisomers, or solvates, or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, T, L, W, X, Y and A are as defined herein for the for treatment of conditions mediated by the blockade of an epithelial sodium channel, particularly an inflammatory or allergic condition.Type: ApplicationFiled: December 20, 2006Publication date: December 18, 2008Inventors: Stephen Paul Collingwood, Nichola Smith
-
Publication number: 20080286363Abstract: A medicament comprising, separately or together (A) a compound of formula I in free or salt or solvate form, (B) a glycopyrronium salt; and (C) a compound of formula II for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease.Type: ApplicationFiled: November 20, 2006Publication date: November 20, 2008Inventors: Stephen Paul Collingwood, Barbara Haeberlin
-
Publication number: 20080279948Abstract: A medicament comprising, separately or together (A) a compound of formula I in free or salt or solvate form, wherein W, Rx, Ry, R1, R2, R3, R4, R5, R6 and R7 have the meanings as indicated in the specification; (B) a glycopyrronium salt; and (C) mometasone furoate; for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease.Type: ApplicationFiled: November 20, 2006Publication date: November 13, 2008Applicant: NXP B.V.Inventors: Stephen Paul Collingwood, Barbara Haeberlin
-
Publication number: 20080274189Abstract: Medicaments comprising (A) an antimuscarinic agent and (B) a corticosteroid for the treatment of inflammatory or obstructive airways diseases.Type: ApplicationFiled: November 20, 2006Publication date: November 6, 2008Inventors: Stephen Paul Collingwood, Barbara Haeberlin
-
Publication number: 20080267886Abstract: A medicament comprising, separately or together (A) glycopyrrolate; and (B) either a compound of formula I in free or salt or solvate form, wherein W, Rx, Ry, R1, R2, R3, R4, R5, R6 and R7 have the meanings as indicated in the specification, or a compound of formula II in free or salt or solvate form, wherein X has the meaning as indicated in the specification, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease. Pharmaceutical compositions that contain (A) and (B) are also described.Type: ApplicationFiled: May 17, 2005Publication date: October 30, 2008Inventor: Stephen Paul Collingwood
-
Patent number: 7019136Abstract: A compound of formula (I): R1 is hydrogen or alkyl optionally substituted by hydroxy, alkoxy, or alkylthio, R2 is hydrogen, alkyl, hydroxyalkyl, alkylcarbonyloxyalkyl, alkoxyalkyl, alkylthioalkyl, alkenyl, cycloalkylalkyl, heterocyclylalkyl, aralkyl in which the aryl ring thereof is optionally fused to a 5-membered heterocyclic group or is optionally substituted by one or more substituents selected from alkoxy, amino, alkylamino, dialkylamino, acylamino, halogen, hydroxy, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonylamino or dialkylaminosulfonylamino, R3 is hydrogen or alkyl optionally substituted by hydroxy, alkoxy, or alkylthio, R4 is hydrogen or alkyl, R5 is a quinolinyl, isoquinolinyl or oxodihydroisoquinolinyl group optionally fused to a 5-membered heterocyclic group and optionally substituted by one or more substituents selected from halogen, cyano, hydroxy, alkyl, hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, alkoxy, alkylthio, alkenyl, alkoxycarbonyl, alkynyl, carboxyl, acyl,Type: GrantFiled: September 9, 2004Date of Patent: March 28, 2006Assignee: Novartis, AGInventors: Gurdip Bhalay, Stephen Paul Collingwood, Robin Alec Fairhurst, Sylvie Felicite Gomez, Reto Naef, David Andrew Sandham
-
Patent number: 6919337Abstract: A compound of formula (I) R1 is hydrogen or alkyl optionally substituted by hydroxy, alkoxy, or alkylthio, R2 is hydrogen, alkyl, hydroxyalkyl, alkylcarbonyloxyalkyl, alkoxyalkyl, alkylthioalkyl, alkenyl, cycloalkylalkyl, heterocyclylalkyl, aralkyl in which the aryl ring thereof is optionally fused to a 5-membered heterocyclic group or is optionally substituted by one or more substituents selected from alkoxy, amino, alkylamino, dialkylamino, acylamino, halogen, hydroxy, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonylamino or dialkylaminosulfonylamino, R3 is hydrogen or alkyl optionally substituted by hydroxy, alkoxy, or alkylthio, R4 is hydrogen or alkyl, R5 is a quinolinyl, isoquinolinyl or oxodihydroisoquinolinyl group optionally fused to a 5-membered heterocyclic group and optionally substituted by one or more substituents selected from halogen, cyano, hydroxy, alkyl, hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, alkoxy, alkylthio, alkenyl, alkoxycarbonyl, alkynyl, carboxyl, acyl,Type: GrantFiled: August 20, 2003Date of Patent: July 19, 2005Assignee: Novartis, AGInventors: Gurdip Bhalay, Stephen Paul Collingwood, Robin Alec Fairhurst, Sylvie Felicite Gomez, Ret Naef, David Andrew Sandham
-
Publication number: 20040038996Abstract: A compound of formula (I) 1Type: ApplicationFiled: August 20, 2003Publication date: February 26, 2004Inventors: Gurdip Bhalay, Stephen Paul Collingwood, Robin Alec Fairhurst, Sylvie Felicite Gomez, Reto Naef, David Andrew Sandham
-
Publication number: 20030171384Abstract: A compound of formula (I) in free or salt form, where R1 is hydrogen or alkyl optionally substituted by hydroxy, alkoxy, or alkylthio, R2 is hydrogen, alkyl, hydroxyalkyl, alkylcarbonyloxyalkyl, alkoxyalkyl, alkylthioalkyl, alkenyl, cycloalkylalkyl, heterocyclylalkyl, aralkyl in which the aryl ring thereof is optionally fused to a 5-membered heterocyclic group or is optionally substituted by one or more substituents selected from alkoxy, amino, alkylamino, dialkylamino, acylamino, halogen, hydroxy, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonylamino or dialkylaminosulfonylamino, R3 is hydrogen or alkyl optionally substituted by hydroxy, alkoxy, or alkylthio, R4 is hydrogen or alkyl, R5 is a quinolinyl, isoquinolinyl or oxodihydroisoquinolinyl group optionally fused to a 5-membered heterocyclic group and optionally substituted by one or more substituents selected from halogen, cyano, hydroxy, alkyl, hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, alkoxy, alkylthio, alkenyl, alkoxycarbonyl, aType: ApplicationFiled: October 2, 2002Publication date: September 11, 2003Inventors: Gurdip Bhalay, Stephen Paul Collingwood, Robin Alec Fairhurst, Sylvie Felicite Gomez, Reto Naef, David Andrew Sandham
-
Patent number: 6589950Abstract: Disclosed are compounds of the formula in free or salt form, wherein X, R1, R2, R3, and R4 are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of inflammatory or obstructive airways disease.Type: GrantFiled: March 19, 2002Date of Patent: July 8, 2003Assignee: Novartis AGInventors: Stephen Paul Collingwood, Judy Hayler, Darren Mark Le Grand, Henri Mattes, Keith Allan Menear, Clive Victor Walker, Xiao-Ling Cockcroft
-
Patent number: 6562960Abstract: An oligonucleotide analogue having 10 to 200 natural and/or synthetic nucleoside units, linked by internucleoside linkages, at least one of the internucleoside linkages being of formula where the indicated methylene group is attached to a 3′ carbon atom of a nucleoside, the indicated oxygen atom is attached to a 5′-carbon atom of an adjacent nucleside, R1 is hydrogen, hydroxy, O—, thiol, S—, —NH2 or a group of formula R1a, —OR1a, —SR1a, —NHR1b, or —NR1bR1c wherein R1a is an unsubstituted or substituted C1 to C10 alkyl, C2 to C10 alkenyl, C3 to C8 cycloalkyl, C6 to C10 aryl or C7 to C13 aralkyl group; and R1b and R1c are each independently an unsubstituted or substituted C1 to C10 alkyl, C2 to C10 alkenyl, C3 to C8 cycloalkyl, C6 to C10 aryl or C7 to C13 aralkyl group or R1b and R1c together with the nitrogen atom to which they are attached denote a five- or six-membered heterocyclic ring, and X is oxygen or sulfur.Type: GrantFiled: October 9, 1998Date of Patent: May 13, 2003Assignee: ISIS Pharmaceuticals, Inc.Inventors: Anthony David Baxter, Stephen Paul Collingwood, Mark Edward Douglas, Roger John Taylor
-
Patent number: 6329519Abstract: A compound of formula (I) wherein B1 is a radical of a nucleoside base, R1 is hydrogen or a hydroxy-protecting group, R2 is hydrogen, hydroxy or a 2′-nucleoside-modifying atom or group, R3 is an unsubstituted or substituted C1 to C10 alkyl, C2 to C10 alkenyl, C4 to C10 cycloalkylalkyl, C6 to C10 aryl or C7 to C13 aralkyl group, and Z is halogen or a group of formula (II) where R4 and R5 are each independently an unsubstituted or substituted C1 to C10 alkyl, C2 to C10 alkenyl, C4 to C10 cycloalkylalkyl, C6 to C10 aryl or C7 to C13 aralkyl group, or R4 is said group and R5 is hydrogen or R4 and R5 together with the nitrogen atom to which they are attached denote a five- to thirteen-membered heterocyclic ring, or Z is a group of formula (III): Nuc-O—, where Nuc is the residue of a natural or synthetic nucleoside or oligonucleotide after removal of a 5′-hydroxyl group therefrom attached through a 5′-methylene thereof to the indicated oxygen atom.Type: GrantFiled: March 15, 1999Date of Patent: December 11, 2001Assignee: ISIS Pharmaceuticals, Inc.Inventors: Stephen Paul Collingwood, Heinz Ernst Moser, Karl-Heinz Altmann, Mark Edward Douglas
-
Patent number: 6087490Abstract: A compound which is a dinucleotide analogue of formula ##STR1## or a salt thereof, where B.sup.1 and B.sup.2 are each independently a monovalent nucleoside base radical,R.sup.1 is hydrogen or Y.sup.1,R.sup.2 and R.sup.3 are each independently hydrogen, halogen, hydroxy or --OY.sup.2,R.sup.4 is hydrogen, halogen, hydroxy, --OY.sup.3 or R.sup.7,R.sup.5 is hydrogen, halogen or R.sup.8,R.sup.6 is hydrogen, Y.sup.4 or a phosphoramidyl group,Z is a group of formula II, III or IV ##STR2## where R.sup.9 is hydrogen, halogen, hydroxy, --OY.sup.5 or R.sup.13, R.sup.10 is hydrogen, halogen or R.sup.14, R.sup.11 is hydroxy, R.sup.15 or --OR.sup.15 where R.sup.15 is a C.sub.1 to C.sub.10 aliphatic group, a C.sub.3 to C.sub.8 cycloaliphatic group, a C.sub.6 to C.sub.10 aromatic group or a C.sub.7 to C.sub.13 araliphatic group, and R.sup.12 is hydrogen, R.sup.12.sub.a or --OCOR.sup.12.sub.a where R.sup.12.sub.a is a C.sub.1 to C.sub.10 aliphatic group, a C.sub.3 to C.sub.8 cycloaliphatic group, a C.sub.6 to C.sub.Type: GrantFiled: October 8, 1998Date of Patent: July 11, 2000Assignee: Novartis AGInventors: Anthony David Baxter, Eric Keith Baylis, Stephen Paul Collingwood, Robin Alec Fairhurst, Roger John Taylor
-
Patent number: 5952478Abstract: A compound of formula (I) or salts thereof, where R.sup.0 is hydrogen or together with R.sup.7 O denotes a C.sub.1 -C.sub.15 hydrocarbylidenedioxy group, R.sup.1 is hydrogen, R.sup.1.sub.a or a group of formula (II), R.sup.1.sub.a is R.sup.1.sub.b or a protecting group Q, R.sup.1.sub.b is C.sub.1 -C.sub.20 alkyl, C.sub.2 -C.sub.20 alkenyl, C.sub.3 -C.sub.10 cycloalkyl, C.sub.6 -C.sub.15 aryl, C.sub.7 -C.sub.16 aralkyl or a 5- or 6-membered heterocyclic group attached by a carbon atom in the heterocyclic group to the indicated phosphorus atom, R.sup.2 is R.sup.2.sub.a or --OR.sup.15 or together with R.sup.5 denotes an oxy group --O--, provided that R.sup.2 is --OR.sup.15 when R.sup.1 is a group of formula (II), R.sup.2.sub.a is a C.sub.1 -C.sub.20 aliphatic group, a C.sub.3 -C.sub.10 cycloaliphatic group, a C.sub.6 -C.sub.15 aromatic group, a C.sub.7 -C.sub.16 araliphatic group, or a 5- or 6-membered heterocyclic group attached by a carbon atom in the heterocyclic group to the indicated phosphorus atom, R.sup.Type: GrantFiled: April 14, 1997Date of Patent: September 14, 1999Assignee: Novartis Finance CorporationInventors: Anthony David Baxter, Roger John Taylor, Stephen Paul Collingwood
-
Patent number: 5670489Abstract: A dinucleotide analogue of formula ##STR1## where B.sup.1 and B.sup.2 are each independently a monovalent nucleoside base radical;R.sup.1 is R.sup.1.sub.a or Z;R.sup.1.sub.a, R.sup.2, R.sup.3 and R.sup.4 are each independently hydrogen, halogen or hydroxy;R.sup.5 is R.sup.5.sub.a or Z;R.sup.6 is hydrogen or R.sup.6.sub.a ;R.sup.7 is hydrogen, alkyl-N,N-dialkylphosphoramidyl or R.sup.7.sub.a, R.sup.8 is R.sup.8.sub.a or Z, or the indicated R.sup.7 O and R.sup.8 together denote an isopropylidenedioxy group;R.sup.5.sub.a and R.sup.8.sub.a are each independently hydrogen, halogen, hydroxy, --OR.sup.10, --OCOR.sup.10 or silyloxy substituted by three C.sub.1 -C.sub.5 hydrocarbyl groups;R.sup.6.sub.a and R.sup.7.sub.a are each independently a C.sub.1 -C.sub.10 aliphatic radical, a C.sub.6 -C.sub.15 aromatic radical, a C.sub.7 -C.sub.30 araliphatic radical, --COR.sup.11, --SO.sub.2 R.sup.11 or silyl substituted by three C.sub.1 -C.sub.15 hydrocarbyl groups;R.sup.9 is hydrogen, a C.sub.1 -C.sub.Type: GrantFiled: June 2, 1995Date of Patent: September 23, 1997Assignee: Novartis CorporationInventors: Anthony David Baxter, Eric Keith Baylis, Stephen Paul Collingwood, Roger John Taylor, Alain De Mesmaeker, Chantal Schmit